The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · see citing works

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,041 · see citing works

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448 · see citing works

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,313 · see citing works

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

Bild, A., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D. A. D., Joshi, M.-B., Harpole, D. H., Lancaster, J. M., Berchuck, A., et al. (2005) · Nature · doi:10.1038/nature04296 · Cited by 2,032 · see citing works

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · see citing works

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650 · see citing works

The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling

Lowenstein, E. J., Daly, R. J., Batzer, A., Li, W., Margolis, B. L., Lammers, R., Ullrich, A., Skolnik, E. Y., Bar‐Sagi, D., & Schlessinger, J. (1992) · Cell · doi:10.1016/0092-8674(92)90167-b · Cited by 1,632 · see citing works

Epidermal growth factor receptor: Mechanisms of activation and signalling

Jorissen, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00098-8 · Cited by 1,565 · see citing works

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538 · see citing works

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517 · see citing works

BRAF mutation predicts sensitivity to MEK inhibition

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,317 · see citing works

Transcriptional Regulation by Extracellular signals: Mechanisms and Specificity

Hill, C. S., & Treisman, R. (1995) · Cell · doi:10.1016/0092-8674(95)90403-4 · Cited by 1,263 · see citing works

A renaissance for SRC

Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113 · see citing works

Nuclear localization of EGF receptor and its potential new role as a transcription factor

Lin, S., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., & Hung, M. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-802 · Cited by 1,064 · see citing works

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B. L., THOMAS, G. V., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 968 · see citing works

An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors

Burgess, A. W., Cho, H., Eigenbrot, C. W., Ferguson, K. M., Garrett, T., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 908 · see citing works

γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase

Ni, C.-Y., Murphy, M. P., Golde, T. E., & Carpenter, G. F. (2001) · Science · doi:10.1126/science.1065412 · Cited by 858 · see citing works

Stat proteins and oncogenesis

Bromberg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15617 · Cited by 846 · see citing works

Intragenic ERBB2 kinase mutations in tumours

Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802 · see citing works

Activation of the Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathway by Conventional, Novel, and Atypical Protein Kinase C Isotypes

Schönwaßer, D. C., Marais, R., Marshall, C. J., & Parker, P. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.790 · Cited by 760 · see citing works

Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer

Baselga, J. M., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 721 · see citing works

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 661 · see citing works

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 550 · see citing works

Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway

Lo, H., Hsu, S.-C., Ali‐Seyed, M., Gündüz, M., Xia, W., Wei, Y., Bartholomeusz, G. A., Shih, J. Y., & Hung, M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.007 · Cited by 539 · see citing works

Hierarchy of Binding Sites for Grb2 and Shc on the Epidermal Growth Factor Receptor

Batzer, A., Rotin, D., Ureña, J. M., Skolnik, E. Y., & Schlessinger, J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.8.5192 · Cited by 479 · see citing works

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes &amp; Development · doi:10.1101/gad.1417406 · Cited by 478 · see citing works

Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer

Haura, E. B., Turkson, J., & Jove, R. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0195 · Cited by 430 · see citing works

MAPKAP kinases — MKs — two's company, three's a crowd

Gaestel, M. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1834 · Cited by 413 · see citing works

EGFR signal transactivation in cancer cells

Fischer, O. M., Hart, S., Gschwind, A., & Ullrich, A. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311203 · Cited by 412 · see citing works

Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer

Baselga, J. M., Albanell, J., Ruı́z, A., Lluch, A. M., Gascón, P., Guillém, V., González, S., Sauleda, S., Marimón, I., Tabernero, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.326 · Cited by 410 · see citing works

EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma

Liu, D., Ghiso, J. A. A., Estrada, Y. D., & Ossowski, L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00072-7 · Cited by 392 · see citing works

Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit

Carpenter, C. L., Auger, K. R., Chanudhuri, M., Yoakim, M., Schaffhausen, B. S., Shoelson, S. E., & Cantley, L. C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98375-4 · Cited by 388 · see citing works

Regulation of MAP kinase activity by peptide receptor signalling pathway: Paradigms of multiplicity

Liebmann, C. (2001) · Cellular Signalling · doi:10.1016/s0898-6568(01)00192-9 · Cited by 291 · see citing works

Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer

Lo, H., Xia, W., Wei, Y., Ali‐Seyed, M., Huang, S.-F. K., & Hung, M. (2005) · Cancer Research · doi:10.1158/0008-5472.338.65.1 · Cited by 287 · see citing works

An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor

Kobayashi, S., Ji, H., Yuza, Y., Meyerson, M., Wong, K.-K., Tenen, D. G., & Halmos, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1346 · Cited by 272 · see citing works

Endosomal Transport of ErbB-2: Mechanism for Nuclear Entry of the Cell Surface Receptor

Giri, D. K., Ali‐Seyed, M., Li, L., Lee, D., Ling, P., Bartholomeusz, G. A., Wang, S., & Hung, M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.11005-11018.2005 · Cited by 242 · see citing works

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation

Anido, J., Scaltriti, M., Bech Serra, J. J., Josefat, B. S., Rojo Todo, F., Baselga, J., & Arribas, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601191 · Cited by 231 · see citing works

Treatment for Advanced Tumors: Src Reclaims Center Stage

Summy, J. M., & Gallick, G. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2692 · Cited by 224 · see citing works

Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation.

Hallberg, B., Rayter, S., & Downward, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41718-2 · Cited by 223 · see citing works

c-erbB-3

Offterdinger, M., Schöfer, C., Weipoltshammer, K., & Grunt, T. W. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200109033 · Cited by 208 · see citing works

The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway

Mattoon, D., Lamothe, B., Lax, I., & Schlessinger, J. (2004) · BMC Biology · doi:10.1186/1741-7007-2-24 · Cited by 207 · see citing works

Co‐regulation of B‐Myb expression by E2F1 and EGF receptor

Hanada, N., Lo, H., Day, C., Pan, Y., Nakajima, Y., & Hung, M. (2005) · Molecular Carcinogenesis · doi:10.1002/mc.20147 · Cited by 188 · see citing works

Hierarchy of Binding Sites for Grb2 and Shc on the Epidermal Growth Factor Receptor

Batzer, A., Rotin, D., Ureña, J. M., et al. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.8.5192-5201.1994 · Cited by 170 · see citing works

The Role of Individual SH2 Domains in Mediating Association of Phospholipase C-γ1 with the Activated EGF Receptor

Chattopadhyay, A., Vecchi, M., Ji, Q.-S., Mernaugh, R. L., & Carpenter, G. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26091 · Cited by 146 · see citing works

High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor

Fujimoto, N., Wislez, M., Zhang, J., Iwanaga, K., Dackor, J., Hanna, A. E., Kalyankrishna, S., CODY, D. D., Price, R. E., Sato, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1977 · Cited by 146 · see citing works

Expression and Nuclear Localization of ErbB3 in Prostate Cancer

Koumakpayi, I. H., Diallo, J., Page, C. L., Lessard, L., Gleave, M. E., Bégin, L. R., Mes‐Masson, A., & Fred Saad, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2242 · Cited by 140 · see citing works

Momentous sprint at the 2156 Olympics?

Tatem, A. J., Guerra, C. A., Atkinson, P. M., & Hay, S. I. (2004) · Nature · doi:10.1038/431525a · Cited by 140 · see citing works

Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.

Rojo, F., Tabernero, J., Albanell, J., Cutsem, E. V., Ohtsu, A., Doi, T., Koizumi, W., Shirao, K., Takiuchi, H., Cajal, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2424 · Cited by 137 · see citing works

Phospholipase C-γ: diverse roles in receptor-mediated calcium signaling

Patterson, R. L., van Rossum, D. B., Nikolaidis, N., Gill, D. L., & Snyder, S. H. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.10.005 · Cited by 121 · see citing works

Responsiveness to Cetuximab without Mutations inEGFR

Tsuchihashi, Z., Khambata‐Ford, S., Hanna, N. H., & Janne, P. A. (2005) · New England Journal of Medicine · doi:10.1056/nejm200507143530218 · Cited by 118 · see citing works

EGFR inhibitors: what have we learned from the treatment of lung cancer?

Giaccone, G., & Rodríguez, J. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0341 · Cited by 83 · see citing works

Functional implication of the interaction between EGF receptor and C-SRC

Leu, T. (2003) · Frontiers in bioscience · doi:10.2741/980 · Cited by 77 · see citing works

Regulation of Proliferation and Apoptosis by Epidermal Growth Factor and Protein Kinase C in Human Ovarian Surface Epithelial Cells

McClellan, M. C., Kievit, P., Auersperg, N., et al. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4328 · Cited by 55 · see citing works

EGF receptor inhibition: Attacks on multiple fronts

Hubbard, S. R. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.004 · Cited by 47 · see citing works

Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: FISH results

Felip, E., Rojo, F., Reck, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7160 · Cited by 7 · see citing works

<i>KRAS</i> and <i>BRAF</i> Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

Richman, S. D., Seymour, M. T., Chambers, P., Elliott, F., Daly, C. L., Meade, A. M., Taylor, G., Barrett, J. H., & Quirke, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4295 · Cited by 560 · see citing works

Molecular targeted therapy for anticancer treatment

Min, H.-Y., & Lee, H.-Y. (2022) · Experimental &amp; Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569 · see citing works

Prevalence and Heterogeneity of <i>KRAS, BRAF</i>, and <i>PIK3CA</i> Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

Baldus, S. E., Schaefer, K.-L., Engers, R., Hartleb, D., Stoecklein, N. H., & Gabbert, H. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2446 · Cited by 432 · see citing works

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

Zhang, N., Zeng, Y., Du, W., Zhu, J., Shen, D., Liu, Z., & Huang, J.-A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3632 · Cited by 362 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

Knijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291 · see citing works

EGFR family: Structure physiology signalling and therapeutic targets ^†

Burgess, A. W. (2008) · Growth Factors · doi:10.1080/08977190802312844 · Cited by 288 · see citing works

EGF-Induced ERK Activation Promotes CK2-Mediated Disassociation of α-Catenin from β-Catenin and Transactivation of β-Catenin

Ji, H., Wang, J., Nika, H., Hawke, D., Keezer, S., Ge, Q., Fang, B., Fang, X., Fang, D., Litchfield, D. W., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.034 · Cited by 270 · see citing works

Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression?

Turley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1089 · Cited by 253 · see citing works

HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

Liska, D., Chen, C.-T., Bachleitner-Hofmann, T., Christensen, J. G., & Weiser, M. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0568 · Cited by 176 · see citing works

Crosstalk between intracellular and extracellular signals regulating interneuron production, migration and integration into the cortex

Peyre, E., Silva, C. G., & Nguyen, L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00129 · Cited by 51 · see citing works

<i>In vitro</i> combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells

Luca, T., Barresi, V., Privitera, G., Musso, N., Caruso, M., Condorelli, D. F., & Castorina, S. (2014) · Cell Proliferation · doi:10.1111/cpr.12125 · Cited by 27 · see citing works

Panitumumab interaction with<scp>TAS</scp>‐102 leads to combinational anticancer effects via blocking of<scp>EGFR</scp>‐mediated tumor response to trifluridine

Baba, Y., Tamura, T., Satoh, Y., Gotou, M., Sawada, H., Ebara, S., Shibuya, K., Soeda, J., & Nakamura, K. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12074 · Cited by 23 · see citing works

Supplementary Data from Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

Desbois‐Mouthon, C., Baron, A., Eggelpoël, M.-J. B.-V., et al. (2023) · doi:10.1158/1078-0432.22440748

Targeting insulin-like growth factor 1 receptor in sarcomas

Scotlandi, K., & Picci, P. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328302edab · Cited by 105 · see citing works

Effect of a mutation at tyrosine 950 of the insulin-like growth factor I receptor on the growth and transformation of cells.

Miura, M., Li, S., & Baserga, R. (1995) · PubMed · Cited by 46 · see citing works

Molecular Mechanisms of Insulin‐like Growth Factor I Receptor Function: Implications for Normal Physiology and Pathological States

LeRoith, D., Blakesley, V. A., & Werner, H. (1999) · Comprehensive physiology · doi:10.1002/cphy.cp070520

Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation

Stock, A.-M., Hahn, S. A., Troost, G., Niggemann, B., Zänker, K. S., & Entschladen, F. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.04.022 · Cited by 16 · see citing works